After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

For healthcare providers, the introduction of datopotamab deruxtecan-dlnk adds to the growing arsenal of targeted therapies for advanced breast cancer. The Trop-2-directed mechanism of action offers a ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

Another possible mechanism of action is the preferential exertion of antibody- dependent cellular cytotoxicity on HER2-overexpressing cancer cells. [62] Trastuzumab contains an immunoglobulin G1 ...

fam-trastuzumab deruxtecan-nxki and datopotamab deruxtecan in collaboration with Daiichi Sankyo; savolitinib in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and ...

Although initially developed to target HER2-positive breast cancer, trastuzumab deruxtecan ... to the ‘bystander effect’. This mechanism refers to the ability of T-DXd to deliver its cytotoxic payload ...